NCT01350128 - PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

May 1, 2011

Primary Completion Date

October 1, 2011

Study Completion Date

October 1, 2011

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

PT001 MDI

PT001 MDI administered as two puffs BID for 7 days

DRUG

Ipratropium Bromide HFA Inhalation Aerosol

Taken as 2 inhalations of the 17 µg per actuation strength MDI QID

OTHER

Placebo MDI

Matching placebo to PT001 MDI administered as two puffs BID for 7 days

Trial Locations (8)

Pearl Investigative Site, Panama City

Pearl Investigative Site, Winter Park

Pearl Investigative Site, Cherry Hill

Pearl Investigative Site, Summit

Pearl Investigative Site, Charlotte

Pearl Investigative Site, Medford

Pearl Investigative Site, Longview

Pearl Investigative Site, Richmond